Research Analysts Offer Predictions for ALNY Q3 Earnings

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Analysts at HC Wainwright reduced their Q3 2026 EPS estimates for Alnylam Pharmaceuticals in a research note issued to investors on Tuesday, August 4th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will post earnings of $1.65 per share for the quarter, down from their prior forecast of $1.79. HC Wainwright currently has a “Buy” rating and a $455.00 target price on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is $6.60 per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals’ Q4 2026 earnings at $1.97 EPS, FY2026 earnings at $6.30 EPS, FY2027 earnings at $9.50 EPS, FY2028 earnings at $10.55 EPS, FY2029 earnings at $14.88 EPS and FY2030 earnings at $19.42 EPS.

A number of other equities analysts have also recently commented on ALNY. Royal Bank Of Canada reduced their target price on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price target on the stock in a research note on Monday. Stifel Nicolaus dropped their price target on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Chardan Capital reissued a “buy” rating and issued a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Finally, Barclays decreased their price objective on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a report on Monday. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $396.72.

Alnylam Pharmaceuticals Trading Down 5.5%

ALNY stock opened at $216.12 on Friday. The company has a current ratio of 3.05, a quick ratio of 3.06 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals has a 12-month low of $197.81 and a 12-month high of $495.55. The stock has a market cap of $28.92 billion, a price-to-earnings ratio of 40.17 and a beta of 0.30. The business’s 50-day moving average is $281.78 and its 200 day moving average is $306.88.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares in the company, valued at $473,302.76. This represents a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MV Capital Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $25,000. HM Payson & Co. acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $27,000. Golden State Wealth Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter valued at about $29,000. Finally, Manchester Capital Management LLC increased its position in Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 72 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.